A review and additional post-hoc analyses of the incidence and impact of constipation observed in darifenacin clinical trials
Jan Tack,1 Jean-Jacques Wyndaele,2 Greg Ligozio,3 Mathias Egermark41University of Leuven, Gastroenterology Section, Leuven, 2University of Antwerp, Department of Urology, Antwerp, Belgium; 3Novartis Pharmaceuticals Corporation, NJ, USA; 4Roche Diagnostics Scandinavia AB, Bromma, Sweden and formerly...
Main Authors: | Tack J, Wyndaele JJ, Ligozio G, Egermark M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2012-09-01
|
Series: | Drug, Healthcare and Patient Safety |
Online Access: | http://www.dovepress.com/a-review-and-additional-post-hoc-analyses-of-the-incidence-and-impact--a11132 |
Similar Items
-
Darifenacin hydrobromide
by: S. Selvanayagam, et al.
Published: (2009-06-01) -
A Prospective, Comparative Study of the Occurrence and Severity of Constipation with Darifenacin and Trospium in Overactive Bladder
by: Revanna Manjunatha, et al.
Published: (2015-03-01) -
Formulation and In-Vitro Evaluation of Darifenacin Hydrobromide as Buccal Films
by: Ishraq k. Abbas, et al.
Published: (2019-12-01) -
Darifenacin in a real-world practice: results of a 6-month phase IV. trial
by: Tine Hajdinjak, et al.
Published: (2013-05-01) -
Darifenacin Hydrobromide loaded nanostructured lipid carrier for oral administration
by: Ali kathem Ala Allah, et al.
Published: (2018-06-01)